Most of the medication in circulation that people are using is from India. They're the generics.
There's one particular co-formulation of 3TC, d4T, and nevirapine that is very popular. Most of that has been brokered, and the pricing as well has been brokered, by the Clinton Foundation. The Clinton Foundation has worked tirelessly, and it continues to work tirelessly, to ensure the lowest possible price to the greatest number of people. Most countries have benefited from that type of brokerage.
But the virus is not consistent throughout the world, and certainly in west African countries there are certain strains of the virus that do not respond to this fixed-dose combination. They're probably the hardest hit in terms of the cost to procure medications for their population because they need to go to the more expensive second-line therapies. As Richard said, they're going from $150- to $160-a-year regimens to about $1,000-a-year or $2,000-a-year regimens, for the same budget. They can treat only a fraction of the number of people they could have treated if they had a regimen that was affordable.